Synergistic Antitumor Activity of SUMO1 degrader and Oxaliplatin through G6PD Inhibition in Colorectal Cancer
Jung, S.; Roy, R.; Zhao, Y. Q.; OConnell, T. M.; Wohlford, R. K.; Kim, D.; Hao, C.; Bellail, A.
Show abstract
Colorectal cancer (CRC) stands as one of the primary causes of death despite advancements in targeted therapies and chemotherapeutic methods. The oxaliplatin-based chemotherapy, such as the FOLFOX, remains limited by its toxic side effects and the development of drug resistance. The current studies demonstrate redox homeostasis as an important therapeutic target in cancer cells through the discovery of glucose-6-phosphate dehydrogenase (G6PD) as their major controller of oxidative stress and survival. In this study, we investigated the therapeutic potential of HB007 in combination with FOLFOX in CRC. Treatment with HB007 decreased the enzyme activity of G6PD and generated high ROS concentrations, which subsequently induced intrinsic apoptosis. When combined with FOLFOX, which also induces ROS and inhibits G6PD activity, HB007 showed synergistic cytotoxicity in vitro, in colon patient-derived 3D organoids, and in vivo patient-derived xenograft model, including FOLFOX-resistant tumors. The combination treatment mechanistically targeted G6PD activity, disrupted redox balance, and activated apoptosis without affecting G6PD protein level. These findings suggest that G6PD inhibition by HB007 enhances the efficacy of FOLFOX, suggesting a strategy to overcome chemoresistance and improve therapy in advanced CRC.
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer 94%
- Rapid Resistance To Bet Inhibitors Is Mediated By Fgfr1 In Glioblastoma 94%
- Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A 94%
Similar papers in this journal
- A novel triptolide analog downregulates NF-κB and induces mitochondrial apoptosis pathways in human pancreatic cancer 96%
- ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 95%
- A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53 95%
Similar papers in this journal
- Small Molecule Screen Identifies Pyrimethamine as an Inhibitor of NRF2-driven Esophageal Hyperplasia 96%
- Epidermal Growth Factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium 96%
- Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies. 95%
Similar papers in this journal
- A Non-genetic Mechanism for Chemoresistance in Lung Cancer: The Role of Integrin β4/Paxillin Axis 94%
- NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma 93%
- Development of Small Molecule Inhibitors Targeting PBX1 Transcription Signaling as a Novel Cancer Therapeutic Strategy 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.